Case studies

Data Compendium for MDM2 Inhibitors

Overview

This case study outlines Excelra’s data curation and biomarker discovery capabilities applied to the identification of pharmacodynamic (PD) biomarkers for MDM2 inhibitors. Leveraging domain-specific text mining and structured extraction pipelines, we curated and analyzed scientific literature to generate actionable insights for precision oncology research focused on solid tumors.

Our client

Our client

A pharmaceutical company based in the EU, focused on antiviral development and expanding its R&D scope into precision oncology, sought Excelra’s expertise to curate a comprehensive list of pharmacodynamic biomarkers associated with MDM2 inhibitor compounds. The goal was to support target validation in tumor types such as prostate, lung, breast, and liver melanoma.

Client’s challenge

Client’s challenge

The client needed a curated dataset of both clinical and pre-clinical PD biomarkers for MDM2 inhibitors. Specific challenges included:

  • Identifying relevant compounds from published literature for prostate, lung, breast, and melanoma in liver cancers.
  • Excluding liquid tumors and sarcomas from the scope.
  • Developing a lexicon for pharmacodynamic biomarker terms and MDM2 inhibitor synonyms to support scalable text mining.
  • Filtering results to include only high-confidence data relevant for precision oncology programs.
Client’s goals

Client’s goals

  • Compile a structured biomarker discovery dataset for solid tumors linked to MDM2 inhibitors.
  • Identify pharmacodynamic biomarkers from pre-clinical and clinical studies.
  • Enable internal research teams with a validated list of PD biomarker associations per compound and tumor indication.
  • Deliver insights that can inform translational strategies in precision oncology.

Our approach

Excelra applied a domain-specific data curation pipeline that included:

Article Identification & Shortlisting-

Curated scientific literature focused on MDM2 inhibitors and PD biomarkers using structured keyword filters.

Lexicon Development-

Generated term lists and synonyms for pharmacodynamic biomarkers, compounds, and targets to enhance recall and precision in text mining.

Concept Extraction-

Captured data concepts such as:

  • PD biomarkers
  • Pre-clinical models
  • Translational relevance
  • Indication-specific compound activity

Data Structuring-

Mapped findings into a standardized Excel format to enable rapid downstream analysis for oncology R&D teams.

Pharmacodynamic Biomarker Discovery for MDM2 Inhibitors
Pharmacodynamic Biomarker Discovery for MDM2 Inhibitors
Pharmacodynamic Biomarker Discovery for MDM2 Inhibitors
Pharmacodynamic Biomarker Discovery for MDM2 Inhibitors
Pharmacodynamic Biomarker Discovery for MDM2 Inhibitors
Pharmacodynamic Biomarker Discovery for MDM2 Inhibitors

Conclusion

Excelra delivered a curated PD biomarker dataset with strong relevance for MDM2 inhibitors across prostate, lung, breast, and melanoma tumor models. The results included:

  • A structured Excel sheet mapping pharmacodynamic biomarker associations.
  • A PowerPoint deck summarizing key insights and oncology-specific trends.
  • A reference list of high-confidence studies aligned to precision oncology targets.

This project reinforces Excelra’s expertise in biomarker discovery, data curation, and domain-driven pharmacodynamic biomarker extraction to support drug development in oncology.